Audentes Therapeutics Annual Revenue, Competitors, Number of Employees and Funding
Estimated Revenue & Financials
- Audentes Therapeutics's estimated annual revenue is currently $26.7M per year.
- Audentes Therapeutics received $172.5M in venture funding in October 2018.
- Audentes Therapeutics's estimated revenue per employee is $96,945
- Audentes Therapeutics's total funding is $212.5M.
- Audentes Therapeutics has 275 Employees.
- Audentes Therapeutics grew their employee count by 19% last year.
- Audentes Therapeutics currently has 43 job openings.
|Donald Wuchterl||Senior Vice President Of Technical Operations||Email Available|
|Eric Mosbrooker||Svp & Chief Commercial Officer||Email Available|
|David Gray||Senior Director Process Development||Email Available|
|Nick Grundy||Senior Director, Head Of It||Email Available|
|Igor Kopman||Sr. Manager, Accounting||Email Available|
|Mary Newman||SVP/Regulatory Affairs||Email Available|
|Jacob Claridge||Manager, Process Engineering||Email Available|
|Fabrizia Urbinati||Director Of Discovery Biology||Email Available|
|Andrew Fong||Manager, Upstream Process Development||Email Available|
|Caroline Finlay||Sr. Clinical Trial Manager||Email Available|
What Is Audentes Therapeutics?
Audentes is a biotechnology company committed to the development and commercialization of innovative new medicines for people with serious, rare muscle diseases. We are a passionate, energetic team driven by the goals of improving the lives of patients and building a successful business. We take pride in strong, global relationships with the patient, research, and medical communities. If you are interested in learning more about our company, please do not hesitate to contact us.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$27.6M||178||8%||N/A|
|Full Spectrum A...||$6.5M||42||5%||N/A|
Audentes Therapeutics News
SAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company ...
In trading on Wednesday, shares of Audentes Therapeutics Inc (Symbol: BOLD) entered into oversold territory, hitting an RSI reading of 28.9, ...
On Thursday, shares of Audentes Therapeutics, Inc. (NASDAQ:BOLD) marked $31.02 per share versus a previous $29.62 closing price.
Audentes Therapeutics Funding
|2013-07-22||$30.0M||A||OrbiMed Advisors, 5AM Ventures||Article|
|2018-01-24||$172.5M||Undisclosed||BofA Merrill Lynch||Article|
|2018-01-26||$231.4M||Undisclosed||BofA Merrill Lynch||Article|
|2018-10-10||$172.5M||Undisclosed||BofA Merrill Lynch||Article|
Audentes Therapeutics Executive Hires
|2014-03-05||Suyash Prasad||SVP/Chief Medical Officer||Article|
|2017-05-09||John Gray||SVP/Chief Scientific Officer||Article|
|2017-07-19||Fulvio Mavilio||VP scientific affairs, Europe||Article|
|2018-05-09||Natalie Holles||President/Chief Operating Officer||Article|
|2019-01-04||Eric Mosbrooker||SVP/Chief Commercial Officer||Article|